DE60229640D1 - Lipoxin analoge als neue inhibitoren der angiogenese - Google Patents

Lipoxin analoge als neue inhibitoren der angiogenese

Info

Publication number: DE60229640D1
Authority: DE; Germany
Prior art keywords: lxa; angiogenesis; new inhibitors; lipoxin; epi
Prior art date: 2001-03-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60229640T

Other languages

English (en)

Inventor

Charles N Serhan

Iolanda M Fierro

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Brigham and Womens Hospital Inc

Original Assignee

Brigham and Womens Hospital Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-02

Filing date

2002-03-01

Publication date

2008-12-11

2002-03-01 Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc

2008-12-11 Application granted granted Critical

2008-12-11 Publication of DE60229640D1 publication Critical patent/DE60229640D1/de

2022-03-02 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE60229640T 2001-03-02 2002-03-01 Lipoxin analoge als neue inhibitoren der angiogenese Expired - Lifetime DE60229640D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US27293101P	2001-03-02	2001-03-02
PCT/US2002/006404 WO2002070068A2 (en)	2001-03-02	2002-03-01	Lipoxin analogs as novel inhibitors of angiogenesis
US10/086,609 US6627658B2 (en)	2001-03-02	2002-03-01	Lipoxin analogs as novel inhibitors of angiogenesis

Publications (1)

Publication Number	Publication Date
DE60229640D1 true DE60229640D1 (de)	2008-12-11

Family

ID=26774943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60229640T Expired - Lifetime DE60229640D1 (de)	2001-03-02	2002-03-01	Lipoxin analoge als neue inhibitoren der angiogenese

Country Status (11)

Country	Link
US (4)	US6627658B2 (de)
EP (2)	EP2221089A1 (de)
JP (3)	JP2005508282A (de)
AT (1)	ATE412448T1 (de)
AU (1)	AU2002252175A1 (de)
CY (1)	CY1108670T1 (de)
DE (1)	DE60229640D1 (de)
DK (1)	DK1406698T3 (de)
ES (1)	ES2316553T3 (de)
PT (1)	PT1406698E (de)
WO (1)	WO2002070068A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4932116B2 (ja)	2000-02-16	2012-05-16	ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド	アスピリン誘発脂質メディエータ
AU2001249329A1 (en)	2000-03-20	2001-10-03	Brigham And Women's Hospital	Lipoxin analogs and methods for the treatment of periodontal disease
DE60229640D1 (de) *	2001-03-02	2008-12-11	Brigham & Womens Hospital	Lipoxin analoge als neue inhibitoren der angiogenese
US8722654B2 (en)	2001-03-02	2014-05-13	The Brigham And Women's Hospital, Inc.	Lipoxin analogs as novel inhibitors of angiogenesis
US7902257B2 (en) *	2002-04-01	2011-03-08	University Of Southern California	Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en)	2002-04-01	2013-07-09	University Of Southern California	Trihydroxy polyunsaturated eicosanoid derivatives
AU2003258194B2 (en) *	2002-08-12	2009-11-12	The Brigham And Women's Hospital, Inc.	Resolvins: biotemplates for therapeutic interventions
US7759395B2 (en) *	2002-08-12	2010-07-20	The Brigham And Women's Hospital, Inc.	Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) *	2003-03-05	2004-09-16	The Brigham And Women's Hospital Inc.	Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US20050238589A1 (en) *	2004-04-14	2005-10-27	Van Dyke Thomas E	Methods and compositions for preventing or treating periodontal diseases
PL1809270T3 (pl) *	2004-11-09	2010-08-31	Alcon Inc	Kwas 5,6,7-trihydroksyheptanowy i jego analogi do leczenia chorób oczu i chorób związanych z odpowiedziami hiperproliferacyjnymi i angiogenicznymi
WO2007041440A2 (en)	2005-10-03	2007-04-12	The Brigham And Women's Hospital, Inc.	Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
US8636986B2 (en) *	2005-11-18	2014-01-28	The Forsyth Institute	Treatment and prevention of bone loss using resolvins
EP2012828A2 (de) *	2006-04-28	2009-01-14	Resolvyx Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von herz-kreislauf-rkrankungen
KR20090040323A (ko) *	2006-07-19	2009-04-23	레솔빅스 파마슈티칼즈, 인코퍼레이티드	점막염의 치료를 위한 조성물과 방법
EP2131833A2 (de) *	2006-10-26	2009-12-16	Resolvyx Pharmaceuticals, Inc.	Verwendung von resolvinen zur hemmung von knochenschwund
US20080161275A1 (en) *	2006-12-05	2008-07-03	Resolvyx Pharmaceuticals, Inc.	Compositions and methods for the treatment of inflammatory disease
BRPI0814858B1 (pt) *	2007-08-08	2017-04-11	Basf Se	formulação em microemulsão aquosa, uso de uma formulação, e, métodos para combater organismos nocivos, para proteger colheitas contra o ataque ou a infestação por pragas nocivas, e, para proteger sementes contra o ataque ou a infestação por pragas nocivas.
WO2009038671A2 (en) *	2007-09-14	2009-03-26	Resolvyx Pharmaceuticals, Inc.	Oxylipin compounds for treating autoimmune diseases
KR20150115959A (ko) *	2007-10-12	2015-10-14	레솔빅스 파마슈티칼즈, 인코퍼레이티드	안과 질환의 치료를 위한 옥실리핀 화합물
EP2219638A2 (de) *	2007-10-29	2010-08-25	Board of Supervisors of Louisiana State University and Agricultural and Mechanical College	Lipoxin-a4-schutz für retinazellen
US7601693B2 (en) *	2008-02-05	2009-10-13	National Taiwan University	Composition for treating cancer and use thereof
US20100105772A1 (en) *	2008-04-25	2010-04-29	Serhan Charles N	Use of novel lipid mediators to inhibit angiogenesis
WO2014130908A1 (en) *	2013-02-22	2014-08-28	University Of Southern California	Methods for treatment of ophthalmic diseases and disorders
SG11201507515YA (en) *	2013-03-15	2015-10-29	Marcus Kare Torleif Larsson	Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
EP3020398A1 (de) *	2014-11-17	2016-05-18	Nitto Denko Corporation	Verbindungen und Zusammensetzungen zur Verminderung von Narbenbildung
CA3026264A1 (en)	2016-06-03	2017-12-07	Thetis Pharmaceuticals Llc	Compositions and methods relating to salts of specialized pro-resolving mediators
US11542473B2 (en)	2016-10-21	2023-01-03	Amniotics Ab	Methods and compositions for generating hematopoietic cells
WO2018144316A1 (en)	2017-01-31	2018-08-09	The Brigham And Women's Hospital, Inc.	Alx receptor ligands define a biochemical endotype for inflammation-based diseases
US11439615B2 (en) *	2017-03-09	2022-09-13	University Health Network	Lipoxin and lipoxin analogue mediated neuroprotection and treatments
KR20220104682A (ko)	2019-10-18	2022-07-26	암니오틱스 아베	양수로부터 양수 간엽 줄기 세포 및 이로부터 유도된 세포를 얻기 위한 프로세스 및 장치
IL315234A (en)	2022-03-03	2024-10-01	Thetis Pharmaceuticals Llc	Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4560514A (en)	1984-05-04	1985-12-24	Bengt Samuelsson	Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en)	1984-06-01	1986-03-18	The Upjohn Company	Anti-inflammatory lipoxin B analogs
US4780281A (en)	1985-06-14	1988-10-25	Wayne State University	Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja)	1986-02-26	1987-09-02	Nissan Chem Ind Ltd	テトラオ−ル誘導体
JPH0739368B2 (ja)	1986-10-01	1995-05-01	旭硝子株式会社	２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en)	1987-07-08	1994-05-24	Nissan Chemical Industries, Ltd.	Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja)	1988-03-10	1989-09-12	Fumie Satou	γ−シリルアリルアルコール及びその製造法
US5079261A (en)	1989-04-28	1992-01-07	Brigham And Women's Hospital	Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja)	1990-01-30	1998-12-09	帝人株式会社	リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en)	1991-02-04	1994-06-21	The Rockefeller University	Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en)	1991-04-01	1997-07-22	Madara; James L.	Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja)	1993-01-20	2001-11-12	富士電機株式会社	自動販売機
US5441951A (en)	1994-06-15	1995-08-15	Brigham & Women's Hospital	Lipoxin compounds
US6048897A (en)	1993-06-15	2000-04-11	Brigham And Women's Hospital	Lipoxin compounds and their use in treating cell proliferative disorders
JPH08512023A (ja) *	1993-06-15	1996-12-17	ブリガム・アンド・ウイメンズ・ホスピタル	リポキシン化合物
AU7215294A (en) *	1993-06-29	1995-01-24	Brigham And Women's Hospital	Modulation of inflammation related to columnar epithelia
US5750354A (en)	1994-03-11	1998-05-12	Brigham And Women's Hospital	Lipoxin transport system and uses therefor
ATE196314T1 (de) *	1996-10-25	2000-09-15	Us Health	Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
US5837283A (en) *	1997-03-12	1998-11-17	The Regents Of The University Of California	Cationic lipid compositions targeting angiogenic endothelial cells
WO2000009503A1 (en) *	1998-08-13	2000-02-24	Merck & Co., Inc.	Integrin receptor antagonists
DE60022327T2 (de) *	1999-03-18	2006-06-29	The Brigham And Women's Hospital Inc., Boston	Lipoxinverbindungen und ihre anwendung
DE60024242T2 (de) *	1999-03-18	2006-12-14	The Brigham And Women's Hospital Inc., Boston	Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion
JP4932116B2 (ja) *	2000-02-16	2012-05-16	ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド	アスピリン誘発脂質メディエータ
AU2001249329A1 (en)	2000-03-20	2001-10-03	Brigham And Women's Hospital	Lipoxin analogs and methods for the treatment of periodontal disease
DE60229640D1 (de)	2001-03-02	2008-12-11	Brigham & Womens Hospital	Lipoxin analoge als neue inhibitoren der angiogenese

2002
- 2002-03-01 DE DE60229640T patent/DE60229640D1/de not_active Expired - Lifetime
- 2002-03-01 WO PCT/US2002/006404 patent/WO2002070068A2/en active Application Filing
- 2002-03-01 AT AT02721234T patent/ATE412448T1/de active
- 2002-03-01 EP EP10003357A patent/EP2221089A1/de not_active Ceased
- 2002-03-01 ES ES02721234T patent/ES2316553T3/es not_active Expired - Lifetime
- 2002-03-01 DK DK02721234T patent/DK1406698T3/da active
- 2002-03-01 EP EP02721234A patent/EP1406698B1/de not_active Expired - Lifetime
- 2002-03-01 PT PT02721234T patent/PT1406698E/pt unknown
- 2002-03-01 JP JP2002569237A patent/JP2005508282A/ja not_active Withdrawn
- 2002-03-01 AU AU2002252175A patent/AU2002252175A1/en not_active Abandoned
- 2002-03-01 US US10/086,609 patent/US6627658B2/en not_active Expired - Fee Related
2003
- 2003-07-08 US US10/615,361 patent/US20040053998A1/en not_active Abandoned
2005
- 2005-09-08 US US11/222,458 patent/US8008282B2/en not_active Expired - Fee Related
2007
- 2007-08-13 US US11/837,657 patent/US20080064749A1/en not_active Abandoned
2008
- 2008-12-29 CY CY20081101498T patent/CY1108670T1/el unknown
2009
- 2009-11-09 JP JP2009256184A patent/JP5302856B2/ja not_active Expired - Fee Related
2012
- 2012-09-05 JP JP2012195046A patent/JP2012255025A/ja not_active Ceased

Also Published As

Publication number	Publication date
PT1406698E (pt)	2009-01-12
WO2002070068A3 (en)	2003-12-31
CY1108670T1 (el)	2014-04-09
ATE412448T1 (de)	2008-11-15
WO2002070068A2 (en)	2002-09-12
US20020193431A1 (en)	2002-12-19
US20040053998A1 (en)	2004-03-18
EP1406698A2 (de)	2004-04-14
DK1406698T3 (da)	2009-02-09
AU2002252175A1 (en)	2002-09-19
JP2012255025A (ja)	2012-12-27
JP2005508282A (ja)	2005-03-31
JP5302856B2 (ja)	2013-10-02
US20080064749A1 (en)	2008-03-13
EP1406698B1 (de)	2008-10-29
JP2010059183A (ja)	2010-03-18
EP2221089A1 (de)	2010-08-25
US8008282B2 (en)	2011-08-30
US20060009521A1 (en)	2006-01-12
ES2316553T3 (es)	2009-04-16
US6627658B2 (en)	2003-09-30

Publication	Publication Date	Title
DE60229640D1 (de)	2008-12-11	Lipoxin analoge als neue inhibitoren der angiogenese
DK0650960T3 (da)	1997-09-01	Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
DK1257550T3 (da)	2006-03-27	Blodplade-ADP-receptor-inhibitor
SI1780197T1 (sl)	2011-02-28	5-substituirani-2-fenilamino benzamidi kot mek-inhibitorji
DK0699439T3 (da)	1999-12-27	Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
BG105163A (en)	2002-03-29	The use of valproic acid analog for the treatment and prevention of migraine and affective ilness
SA523440403B1 (ar)	2024-10-10	Magl مثبط
DE60236467D1 (de)	2010-07-01	Lipoxinanaloge als neuartige Restenose-Hemmer
YU15002A (sh)	2005-03-15	Upotreba alfa-lipoinske kiseline ili njenih derivata
ATE352317T1 (de)	2007-02-15	Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
EA200501083A1 (ru)	2006-02-24	Соединения, активные в ингибировании пролилолигопептидазы
IL156203A0 (en)	2003-12-23	Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
ATE248607T1 (de)	2003-09-15	Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen

Legal Events

Date	Code	Title	Description
2009-11-19	8364	No opposition during term of opposition